Home  |  About MEFS  |  Annual Meeting  |  Membership  |  Specialty Groups  | News & Publications  |  Education |  Calendar  | Links

In this Issue


   Important to know in 2017

1-Starting menstrual periods at a young age ...

2-Researchers improve technology to save ..

3-100-year-old fertility technique reduces...

4-Technique for 'three-parent baby' revealed

5-Artificial mouse embryo developed in vitro

6-Stem cell therapy in the restoration of ..

7-Hysteroscopy before in-vitro fertilization ...

   Important to learn in 2017

BEST OF ESHRE & ASRM 2017: an emphasis on transatlantic ‘debate’

1-The barriers to treatment faced by ...

2-PGS in recurrent pregnancy loss

3-Value of CCS

4-Embryo selectivity and the function of the..

5-Sperm DNA fragmentation tests

6-Luteal phase support after agonist triggering

   7-Primary Ovarian insufficiency

10th meeting Sudan human reproduction & embryology society

From the Editor

For twenty-four years, the Middle East Fertility Society has been dedicated to expanding the art, science and practice of reproductive medicine in the Arab world and the Middle East.  The MEFS organization is keen to foster the growth of knowledge in this field and promote the best available evidence-based practice.

The last meeting in Sharm El Sheikh on November 4-6, 2016 had witnessed more than 70 oral presentations, given by more than 50 renowned international and regional speakers. Top quality research is always presented in our meetings.  

The Society has always been keen to organize pre-congress courses and symposia in the annual meetings of ASRM and ESHRE and the highest positive impact is always received. Integration and collaboration with the distinguished national societies is among our goals. Our joint meetings with Sudan Human Reproduction and Embryology Society have witnessed a major success.

Supporting and encouraging research is a top priority. MEFS provides a 20,000 USD grant to support research aimed at improving reproductive outcome of infertile couples. Further, Dr. SAMIR ABBAS - MEFS Research Award has been established as an incentive for Middle Eastern young scientists to pursue their research interests in Human Reproduction.

 We are always looking for further expansion and nonstop improvement. We hope to see you all, our valued partners, in the 24th annual meeting in the lovely city of Dubai, September 28-30, 2017.

 Eman Elgindy MD, PhD

Member Societies and readers are invited to send all comments, reports or articles to 

Middle East Fertility Society ,

Achrafieh, P.O.Box :167220, Beirut, Lebanon, Phone: + 961-1-610400, Fax: + 961-1-612400, news@mefs.org


Important to know in 2017


1-Starting menstrual periods at a young age and childlessness increase risk of premature and early menopause

January 24, 2017, Oxford University Press (OUP)

“Women who had their first menstrual period when they were aged 11 or younger have an increased risk of an early or premature menopause and if they remain childless the risk is increased even more, according to results from the first large scale, multi-national study to investigate the links between age at puberty and menopause and whether or not a woman has had children.”


2-Researchers improve technology to save sperm stem cells

Method key to preserving fertility of boys with cancer

 April 6, 2017, Washington State University

Researchers have found a promising way to preserve sperm stem cells so boys could undergo cancer treatment without risking their fertility. Stem cell can produce 5,000 sperm with each heartbeat, mature, fertile men produce some 1,300 sperm cells. They come from a pool of self-renewing spermatogonial stem cells that are present at birth. As each stem cell differentiates, it can produce some 5,000 sperm. Glycolysis is important for the stem cell. Trials were done to change the culture environment to favor glycolysis. By lowering the oxygen in the culture -- adding nitrogen to cut it by more than half -- the researchers found they could dramatically improve the percentage of stem cells capable of making normal sperm when put back into the testes. Where before only 5 percent of the cells remained viable after six months, now 40 percent were viable.”

3-100-year-old fertility technique reduces need for IVF

May 18, 2017, University of Adelaide

Infertile couples have a major opportunity to achieve a successful pregnancy without the need for IVF, thanks to new research into a 100-year-old medical technique. This was hystero-salpingography. Almost 40% of infertile women in the oil group and 29% of infertile women in the water group achieved successful pregnancies within six months of the technique being performed.

4-Technique for 'three-parent baby' revealed

April 3, 2017, Elsevier

“Details of a pioneering IVF technique using mitochondrial replacement therapy (MRT) have been published, giving hope to those families with inheritable mitochondrial disorders that they may be able to have healthy children in the future.”

5-Artificial mouse embryo developed in vitro

March 2017, Science

A structure whose composition and architecture very closely resemble a mouse embryo has been developed in vitro by scientists at the University of Cambridge, in UK

6-Stem cell therapy in the restoration of endometrial function

 ‘Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study’ by Santamaria and colleagues in Hum Reprod Journal 2016

7-Hysteroscopy before in-vitro fertilisation (inSIGHT): a multicentre, randomised controlled trial.

Lancet, June, 2016

Multicentre, randomized controlled trial in seven university hospitals and 15 large general hospitals in the Netherlands, 750 women were randomized to receive either hysteroscopy (n=373) or immediate IVF (n=377). 209 (57%) of 369 women in the hysteroscopy group and 200 (54%) in the immediate IVF group had a livebirth. The conclusion was that routine hysteroscopy does not improve livebirth rates in infertile women with a normal transvaginal ultrasound of the uterine cavity scheduled for a first IVF treatment. Women with a normal transvaginal ultrasound should not be offered routine hysteroscopy.



Important to learn in 2017


BEST OF ESHRE & ASRM 2017: an emphasis on transatlantic ‘debate’


1-The barriers to treatment faced by those living on these two transatlantic continents

 In USA:

There is markedly limited public or insurance-funded options in the US. Culturally, politically and legally the US has taken a ‘hands-off ’ approach to infertility, what Adashi described as a ‘quintessentially American’ libertarian response. 15 state mandates for infertility insurance, many of which will not provide full IVF coverage.

 In Europe:

‘non-economic’ barriers to full care here seem much greater than in the US.  Boivin emphasized low levels of education, the female partner in full employment, ‘reproductive choice’ (‘decisional avoidance’, voluntary childlessness), limited access and of course legal constraints.


2- PGS in recurrent pregnancy loss

 The greatest debate was on the role of PGD and PGS in the diagnosis and prevention of recurrent pregnancy loss (RPL).

 In Europe:

Mariette Goddijn from the Amsterdam Medical Center: reported pregnancy rates after PGS are no higher than after natural conception; that pregnancy rates anyway after natural conception are ‘relatively good’, and that ICSI following PGS is associated with complications and high cost. Goddijn emphasised that the case for expectant management in RPL - or at least the case against PGS - was recently made in a Human Reproduction report in which a retrospective cohort study of 300 RPL patients found similar live birth and miscarriage rates in both the expectant management and PGS groups.

 In USA:

William Kutteh criticized the HR study (retrospective, selection bias, different patient group ages). He claimed that PGS in RPL lay largely in the growing incidence of aneuploidy with female age and the possibility that comprehensive chromosome screening following blastocyst biopsy in good prognosis patients improves embryo selection and implantation rates. This needs centres ‘with significant experience’ in biopsy and testing. Kutteh underscored that the overall value of PGS in unselected patients is still ‘unclear’, its potential value might be (‘promising’) in RPL


3- Value of CCS

 In USA:

 Richard Scott from Reproductive Medicine Associates of New Jersey (whose association with IVI of Valencia was announced just before this meeting) was defending the CCS. Scott recognised ‘real questions’ regarding comprehensive chromosome screening: the safety of taking the embryonic sample; predictive value; mosaicism; and cost. He emphasized that ‘day 3 biopsy will soon be of historic interest only’ and that blastocyst biopsy will increase implantation rate (while cleavage stage biopsy will not). On predictive value, a prospective study performed by Scott’s own group showed that CCS is indeed ‘highly predictive’ of reproductive potential - which in this study was around 98% for negative predictive value at all ages from 32 to 42. His arguments in cases of mosaicism (lower predictive value) and on cost were less persuasive. Scott also presented data reflecting the precision with which PGS can identify subchromosomal defects (duplications and defects) and the impact they are likely to have on outcome if not identified.

Scott was taking part in a debate on whether aneuploid embryos should ever be transferred; his answer was never, provided they are truly aneuploid, which of course requires PGS to verify.

 In Europe:

Siobhan Quenby from the University of Warwick, UK, entertainingly proposed that 'diversity' in the gene pool provided the spice of life - and anyway, she added, the maternal decidua can make embryo selection far better than any laboratory test.


4-Embryo selectivity and the function of the endometrium in early embryo development

 This was presented from one side, which was Nick Macklon from the University of Southampton, UK, on this emerging concept. Macklon’s theme, based on his own work with colleagues at the University of Warwick, was that the endometrium is more than merely ‘receptive’ - that it allows implantation of the healthy embryo but also prevents implantation of the unhealthy embryo and goes on to nourish and incubate the preimplantation embryo. The decidualised stromal cells of the endometrium recognise the incompetent embryo, such that those stromal cells do not migrate to poor quality embryos. This support the concept of the 'choosy' endometrium. This might occur by the endometrium's transcriptional response to developmentally competent and incompetent embryos. In recurrent implantation losses, he suggested, the less choosy ‘superfertile' mothers will experience more miscarriages. 'New concepts are required,' he said, which recognise the active - and not passive - role of the endometrium. The expression of endometrial genes, said Macklon, might yet provide the basis of a new - and finally accurate - test of uterine receptivity.


5- Sperm DNA fragmentation tests

 Herman Tournaye from the VUB Brussels was only lukewarm. He emphasized that DNA fragmentation occurs normally during spermatogenesis.He suggested that, reproductive consequences are just associations, not causations. It is unclear who might benefit, even though the tests seem recommended in couples with repeated ART failure or miscarriage. Tournaye also emphasised that the range of present tests all offer a ‘proxy' result in that the tested sperm cells are thereafter unsuitable for clinical use. Moreover, despite the hype of antioxidants, there are no proven therapies to remedy subfertility associated with high levels of DNA fragmentation in sperm.


6- Luteal phase support after agonist triggering

This was presented by Human Fatemi from IVI Abu Dhabi. He underscored ‘segmentation’ principle for the prevention of OHSS in IVF. Yet, as Fatemi noted, OHSS cases do - albeit rarely - occur with agonist triggering and the likely explanation is severe luteolysis. Luteal support with hCG following the agonist trigger results in good pregnancy rates and low risk of OHSS.


7- Primary Ovarian insufficiency

Aaron Hsueh from Stanford University recalled how genomic and genetic studies implicating hippo signalling genes in POI, PCOS and ovarian reserve had led to the possibility of in vitro activation (IVA) and childbirth in women previously diagnosed with POI. Hsueh and his Japanese colleagues’ work on ovarian physiology and signalling pathways had identified ‘residual follicles’ which could be activated and grown into embryos for implantation and pregnancy. Hsueh found that blocking a protein known as PTEN (in mouse and human ovaries) stirred dormant follicles into life. ‘Our treatment was able to activate or awaken some of the remaining primordial follicles and cause them to release eggs,’ said Hsueh. He reported that three babies had been born in women previously diagnosed with POI. The genome editing technique of CRISPR Cas9 is a long way from clinical use, but it was described by Robin Lovell-Badge of the Francis Crick Institute in London as 'a revolution over the past five years'. He devoted his presentation to the report of the US National Academies of Science, Engineering, and Medicine, whose conclusions reflect a degree of scientific and clinical consensus evident throughout most of this ESHRE/ASRM meeting. Lovell-Badge, a member of the report’s writing group, said progress should not go ahead without guidelines, nor beyond the treatment of disease. ‘Caution is needed,’ he said, ‘but that does not mean prohibition.’